Zobrazeno 1 - 10
of 44
pro vyhledávání: ''
Autor:
Sarah Kirk, Tania Szado, Lukas C. Amler, Young-Hyuck Im, Jennifer Eng-Wong, Giampaolo Bianchini, Pinuccia Valagussa, Tadeusz Pienkowski, Luca Gianni, Giulia Bianchi, Lila Zabaglo, Mitch Dowsett, Astrid Kiermaier, Mei Ching Liu, Ling Ming Tseng
Publikováno v:
Breast Cancer Research : BCR
Background NeoSphere showed significantly higher pathologic complete response (pCR) with neoadjuvant pertuzumab, trastuzumab, and docetaxel compared with trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel. We assess
Autor:
Joseph Geradts, Leonard M. Neckers, Neil L. Spector, Timothy A.J. Haystead, Qing Cheng, H. Kim Lyerly, Jeffrey T. Chang
Publikováno v:
Breast Cancer Research : BCR
Introduction Although human epidermal growth factor receptor 2 (HER2) positive or estrogen receptor (ER) positive breast cancers are treated with clinically validated anti-HER2 or anti-estrogen therapies, intrinsic and acquired resistance to these th
Publikováno v:
Breast Cancer Research : BCR
Introduction Breast cancer comprises clinically distinct subtypes, but most risk statistics consider breast cancer only as a single entity. To estimate subtype-specific lifetime breast cancer risks, we took advantage of population-based data for whic
Autor:
Jhih Rong Lin, Wen Zhang, Rubén Nogales-Cadenas, Zhengdong D. Zhang, Ying Cai, Cristina Montagna, Quanwei Zhang
Publikováno v:
Breast Cancer Research : BCR
Background MicroRNAs (miRNAs) are small non-coding RNA molecules of about 22 nucleotides which function to silence the expression of their target genes. Numerous studies have shown that miRNAs are not only key regulators in important cellular process
Autor:
Melissa A. Crosby, Patricia A. Parker, Kalatu Davies, Robert J. Volk, Isabelle Bedrosian, Abenaa M. Brewster, Susan K. Peterson, Yu Shen, Scott B. Cantor
Publikováno v:
Breast Cancer Research : BCR
Background Family history of breast cancer is associated with an increased risk of contralateral breast cancer (CBC) even in the absence of mutations in the breast cancer susceptibility genes BRCA1/2. We compared quality-adjusted survival after contr
Autor:
Shashank Srivastava, Emad A. Rakha, Gayatri Sharma, Shakur Mohibi, Sameer Mirza, Nicolas I. Griffin, Mohammed A. Aleskandarany, Bhavana J. Dave, Vimla Band, Xiangshan Zhao, Hamid Band
Publikováno v:
Breast Cancer Research : BCR
Background We have established the critical role of ADA3 as a coactivator of estrogen receptor (ER), as well as its role in cell cycle progression. Furthermore, we showed that ADA3 is predominantly nuclear in mammary epithelium, and in ER+, but is cy
Autor:
Kosei Hirakawa, Naoki Aomatsu, Tsutomu Takashima, Katsumi Ikeda, Tetsuro Ishikawa, Masakazu Yashiro, Shinichiro Kashiwagi, Yoshinari Ogawa
Publikováno v:
Breast Cancer Research : BCR
Introduction Triple-negative breast cancer (TNBC), which is characterized by negativity for estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER2), is a high risk breast cancer that lacks specific targets for tre
Publikováno v:
Largent, JA; Ziogas, A; & Anton-Culver, H. (2005). Effect of reproductive factors on stage, grade and hormone receptor status in early-onset breast cancer.. Breast cancer research : BCR, 7(4). doi: 10.1186/bcr1198. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/1hh414hb
Breast Cancer Research
Breast Cancer Research
INTRODUCTION: Women younger than 35 years who are diagnosed with breast cancer tend to have more advanced stage tumors and poorer prognoses than do older women. Pregnancy is associated with elevated exposure to estrogen, which may influence the progr
Autor:
A. Rocca, Elisabetta Munzone, Giuseppe Renne, Aron Goldhirsch, Giuseppe Curigliano, Giuseppina Bonizzi, Franco Nolè
Publikováno v:
Breast Cancer Research
Introduction The amounts of estrogen receptor (ER) and progesterone receptor (PgR) in a primary tumor are predictive of the response to endocrine therapies of breast cancer. Several patients with ER-positive primary tumors relapse after adjuvant endo
Autor:
Jennifer M. Giltnane, Harriet M. Kluger, Yasmine Nadler, Christopher B. Moeder, David L. Rimm, Robert L. Camp, Yuval Kluger
Publikováno v:
Breast Cancer Research : BCR
Introduction Bcl-2 antanogene-1 (Bag-1) binds the anti-apoptotic mediator Bcl-2, and enhances its activity. Bcl-2 and Bag-1 are associated with chemotherapy resistance in cancer cells. Drugs that target Bcl-2 are currently in clinical development. Th